Case Report on Gemcitabine and HUS
Author Information
Author(s): Serke S, Riess H, Oettle H, Huhn D
Primary Institution: Department of Haematology–Oncology, Humboldt-Universität, Berlin, Germany
Hypothesis
Can gemcitabine therapy lead to the development of haemolytic-uraemic syndrome (HUS) in patients with metastatic duodenal papillary carcinoma?
Conclusion
The patient recovered from HUS after treatment and did not experience a recurrence after re-exposure to gemcitabine.
Supporting Evidence
- The patient developed HUS while on gemcitabine therapy.
- The diagnosis of HUS was made on the day of admission.
- The patient recovered after aggressive therapy.
Takeaway
One patient developed a serious condition called HUS while taking a cancer drug, but after treatment, they got better and didn't have the problem again when they took the drug later.
Methodology
The patient was treated with haemodialysis and plasmapheresis.
Participant Demographics
One adult patient with metastatic duodenal papillary carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website